Mizuho reissued their buy rating on shares of Akebia Therapeutics (NASDAQ:AKBA) in a report issued on Tuesday, AnalystRatings.com reports. They currently have a $16.00 price objective on the biopharmaceutical company’s stock.
Several other analysts also recently issued reports on the company. BidaskClub downgraded Akebia Therapeutics from a sell rating to a strong sell rating in a research note on Friday, November 1st. Zacks Investment Research upgraded Akebia Therapeutics from a sell rating to a hold rating in a report on Monday, October 21st. Needham & Company LLC lowered their price target on Akebia Therapeutics from $18.00 to $15.00 and set a buy rating on the stock in a report on Thursday, November 14th. ValuEngine raised shares of Akebia Therapeutics from a sell rating to a hold rating in a research report on Thursday, August 1st. Finally, HC Wainwright reduced their price objective on shares of Akebia Therapeutics from $17.00 to $16.00 and set a buy rating for the company in a research note on Monday. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the company. Akebia Therapeutics currently has a consensus rating of Hold and a consensus price target of $12.71.
NASDAQ:AKBA traded up $0.16 during mid-day trading on Tuesday, reaching $3.34. The stock had a trading volume of 2,588,361 shares, compared to its average volume of 1,047,621. The stock has a market cap of $399.65 million, a P/E ratio of -1.37 and a beta of 1.51. The business’s 50 day moving average is $3.93 and its 200 day moving average is $4.41. The company has a debt-to-equity ratio of 0.06, a current ratio of 1.34 and a quick ratio of 0.82. Akebia Therapeutics has a fifty-two week low of $2.99 and a fifty-two week high of $10.45.
Akebia Therapeutics (NASDAQ:AKBA) last posted its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.37) by ($0.09). The business had revenue of $91.98 million during the quarter, compared to analyst estimates of $93.94 million. Akebia Therapeutics had a negative net margin of 75.39% and a negative return on equity of 32.74%. Equities analysts expect that Akebia Therapeutics will post -1.56 EPS for the current year.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Aperio Group LLC acquired a new stake in Akebia Therapeutics during the second quarter worth $31,000. Tower Research Capital LLC TRC bought a new stake in Akebia Therapeutics in the 3rd quarter valued at $30,000. Wedbush Securities Inc. acquired a new position in shares of Akebia Therapeutics in the 2nd quarter valued at $52,000. AQR Capital Management LLC acquired a new position in shares of Akebia Therapeutics in the 2nd quarter valued at $54,000. Finally, Bank of Montreal Can lifted its holdings in shares of Akebia Therapeutics by 1,478.7% during the 2nd quarter. Bank of Montreal Can now owns 11,856 shares of the biopharmaceutical company’s stock worth $57,000 after acquiring an additional 11,105 shares during the period. Institutional investors and hedge funds own 72.59% of the company’s stock.
Akebia Therapeutics Company Profile
Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its lead product candidate includes Auryxia, a ferric citrate to control the serum phosphorus levels in adult patients with chronic kidney disease (CKD), on dialysis (DD)-CKD, or the hyperphosphatemia indication (HIF); and vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to CKD in DD and non-dialysis patients.
Featured Story: What is the 52-week high/low?
Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.